BREATHOMICS APPROACH TO INVESTIGATE SYSTEMIC SCLEROSIS USING THERMAL DESORPTION AND COMPREHENSIVE TWO-DIMENSIONAL GAS CHROMATOGRAPHY HIGH-RESOLUTION TIME-OF-FLIGHT MASS SPECTROMETRY

LIÈGE université

Thibault **Massenet**[1], Julien **Guiot**[2], Delphine **Zanella**[1], Thibaut **Dejong**[1], Laurie **Giltay**[2], Monique **Henket**[2], Françoise **Guissard**[2], Béatrice **André**[2], Michel **Malaise**[2], Judith **Potjewijd**[3], Florence **Schleich**[2], Renaud **Louis**[2], Jean-François **Focant**[1], Pierre-Hugues **Stefanuto**[1]

1 - Molecular System, Organic & Biological Analytical Chemistry Group, University of Liege, 11 Allee du Six Aout, 4000, Liege, Belgium **2** – Respiratory Medicine, GIGA I3, CHU Liege, 4000, Liege, Belgium **3** – Maastricht University Medical Center, 6229 HX, Maastricht, The Netherlands

KEY POINTS

➢ **Breaths of 100 patients (50 Ssc and 50 SSc-ILD) have been analyzed using a TD-GC×GC-HRTOFMS method.**

➢ **A PLS-DA allowed us to discriminate SSc patients from SSC-ILD ones and to ascertain specific biomarkers.**

➢ **This study tends to confirm a set of biomarkers that have already been observed in our previous research.**

INTRODUCTION

Systemic sclerosis (SSc), is a chronic and heterogenous auto-immune disease characterized by several disorders (inflammation, fibrosis, etc.) involving multiple internal organs.

Furthermore, interstitial lung disease (ILD) is one of the most common types of pulmonary involvement responsible for the disease severity and leading to high morbidity and mortality. ILD is frequently associated with SSc (SSc-ILD). Therefore, it is essential to diagnose patients suffering from SSc-ILD at an early stage. In fact, the reference treatment of SSc-ILD relies on corticosteroids and immunosuppressive therapy to reduce the inflammation-associated ILD. This treatment should therefore exclusively be administered to high-risk SSc-ILD patients.

In a previous research, we demonstrated that a combination of sixteen volatile metabolites in breath could reliably discriminate SSc patients and matched controls (healthy). Furthermore, thermal desorption (TD) coupled with comprehensive two-dimensional gas chromatography – high resolution time-of-flight mass spectrometry (TD-GC×GC-HRTOFMS**)** stands out as the perfect tool for exhaled breath analysis regarding its peak capacity and its ability to correctly identify biomarkers.

WORKFLOW & PRELIMINARY RESULTS

1/ Patients

50 SSc patients   50 SSc-ILD patients

The patients have been recruited and diagnosed at the medical center of the University of Maastricht and the hospital of the University of Liège.

2/ Sampling

A. The patients exhale the air contained in their lungs in a tedlar bag.

B. A low-flow pump is used to transfer all the VOCs onto a sorbent tube (Tenax®GR/Carbopack™B).

3/ Samples analysis

All the VOCs trapped onto the sorbent tubes are finally released and separated into a Pegasus GC-HRT 4D.

GC×GC :
Columns : ¹D Rxi-624Sil MS (30m x 0.25 mm x 1.4 µm d$_f$)
²D Stabilwax (3m x 0.25 mm x 0.5 µm d$_f$)
Temperature prog. : 40°C (5 min), ramped 5°C/min to 235°C (3 min)
Modulator : Quad jet dual-stage, P$_M$= 3.5 s, hot pulse time : 1.05 s

HR-TOFMS :

Acquisition delay : 210 s
Acquisition frequency : 200 Hz
**Electron ionization energy :** 70 eV
Mass range : 29-450 mu

Figure : Representation of the large number of chromatograms acquired during this study (one for each patient).

4/ Data treatment/ Results

After a preliminary data curation on 42 chromatograms (21 SSC vs 21 SSC-ILD), multivariate statistics were applied. Whereas no separation was observed using a PCA, PLS-DA allowed us to statistically separate the two groups of patients and to ascertain important features (biomarkers). Among these biomarkers, some of them have already been observed in our previous research.

Identification (based on library research)	VIP Score
l-Menthone	2.567
Butanoic acid	2.5435
Cyclohexanone, 5-methyl-2-(1-methylethyl)-, cis-	2.5079
Caryophyllene	2.4516
Acetone	2.2813
Cyclohexanol, 1-methyl-4-(1-methylethyl)-	2.2375
Isopropyl Alcohol	2.2004
Cyclohexanol, 5-methyl-2-(1-methylethyl)-, acetate, (1α,2β,5β)-	2.1969
Pyrazine	2.1784
α-Terpineol	2.1638
Heptane, 2-methyl-	2.1135
Benzofuran, 4,5,6,7-tetrahydro-3,6-dimethyl-	2.0397
m-Chloroaniline	2.0375
Linalyl acetate	2.0331
(-)-β-Bourbonene	2.0307
1-Nonanol	2.0166

Figure (top): PLS-DA scores plot based on the training set (21 SSc & 21 SSc-ILD). Figure (bottom): Most important features based on their VIP scores.

CONCLUSION

These preliminary results reinforce the idea that, based on a breathomic approach, a classification of SSc and SSC-ILD patients is possible. In fact, we demonstrated that these two types of patients could be statistically separated using a PLS-DA. Some of the biomarkers observed here were also noticed in our previous study and therefore tend to confirm it. Going forward, we plan to elaborate a robust statistical model, based on the entire cohort of patients, which aims to correctly classify the two types of patients. Moreover, patients suffering from other diseases involving pulmonary fibrosis will also be included in the study.

•D. Zanella et al., "Breathomics to diagnose systemic sclerosis using thermal desorption and comprehensive two-dimensional gas chromatography high-resolution time-of-flight mass spectrometry," *Anal. Bioanal. Chem.*, vol. 413, no. 14, pp. 3813–3822, Jun. 2021, doi: 10.1007/S00216-021-03333-4/FIGURES/3.
•G. Bussone and L. Mouthon, "Interstitial lung disease in systemic sclerosis," *Autoimmun. Rev.*, vol. 10, no. 5, pp. 248–255, Mar. 2011, doi: 10.1016/J.AUTREV.2010.09.012.
•R. Giacomelli et al., "Interstitial lung disease in systemic sclerosis: current and future treatment," *Rheumatol Int*, vol. 3, pp. 853–863, 2017, doi: 10.1007/s00296-016-3636-7.

OBIACHEM Organic and Biological Analytical Chemistry Group

CHU de Liège

Thibault **MASSENET**
thibault.massenet@uliege.be